| dc.creator |
Cicek, M. B. |
|
| dc.creator |
DEDE, Bülent |
|
| dc.creator |
Gorgulu, G. |
|
| dc.date |
2018-01-31T21:00:00Z |
|
| dc.date.accessioned |
2020-10-06T09:50:00Z |
|
| dc.date.available |
2020-10-06T09:50:00Z |
|
| dc.identifier |
4bd14077-113b-4a80-a41f-707ce64a47a5 |
|
| dc.identifier |
10.12693/aphyspola.133.250 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/4bd14077-113b-4a80-a41f-707ce64a47a5/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/59472 |
|
| dc.description |
A novel ligand, N, N ''-(4-methyl-1,2-phenylene)bis(2-(biphenyl-4-yl)-N'-hydroxy-2-oxoacetimidamide) (H2L) with its Cu(II) and Mn(II) complexes were synthesized in this study. All compounds synthesized were also characterized by H-1- and C-13-NMR, the Fourier transform infrared, elemental analysis, inductively coupled plasma optical emission spectrometry, molar conductivity, magnetic susceptibility measurements and thermogravimetric analysis. Vascular endothelial growth factor-2 (VEGFR-2) and cyclooxygenase-2 (COX-2) inhibition is often used as a parameter for being a potent anticancer agent in docking studies. For this purpose, synthesized and characterized ligand was investigated by molecular docking study to test its inhibitory effect against angiogenic factors VEGFR-2 and COX-2. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Novel Aminoketooxime Ligand and Its Cu(II) and Mn(II) Complexes: Synthesis, Characterization and Molecular Docking Studies |
|
| dc.type |
info:eu-repo/semantics/article |
|